Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Rhea-AI Summary

Biomerica (Nasdaq: BMRA) received MHRA registration on March 5, 2026 for its hp+detect™ diagnostic test, authorizing commercial sales in Great Britain.

The test detects Helicobacter pylori; the company is in active discussions with UK partners to access diagnostic labs and will provide updates as agreements are finalized.

Positive

• MHRA registration enables commercial sales in Great Britain
• Expands international reach into the UK diagnostic laboratory market
• Addresses large clinical need for H. pylori diagnostics given high prevalence
• Active partner discussions indicate near-term commercialization pathway

Negative

• None.

Key Figures

US H. pylori prevalence: 35% of population EU5 H. pylori prevalence: 45% of population Global H. pylori prevalence: 44% of population +3 more

6 metrics

US H. pylori prevalence 35% of population Estimated infection rate in the United States

EU5 H. pylori prevalence 45% of population Estimated infection rate in Europe’s five largest countries

Global H. pylori prevalence 44% of population Estimated share of global population affected

WHO priority bacteria count 16 antibiotic-resistant bacteria H. pylori listed among 16 highest global threats

Cancer mortality rank 3rd most common cause Gastric cancer among cancer-related deaths worldwide

Publication date March 05, 2026 Press release date for MHRA hp+detect™ registration

Market Reality Check

Price: $1.97 Vol: Volume 10,348 is 0.71x th...

normal vol

$1.97 Last Close

Volume Volume 10,348 is 0.71x the 20-day average of 14,654, suggesting no pre-news accumulation. normal

Technical BMRA traded at $2.03, below its $2.84 200-day MA, and 65.7% under its 52-week high.

Peers on Argus

Peer moves were mixed: HSCS appeared in momentum scanners moving up ~5% while PA...

1 Up 1 Down

Peer moves were mixed: HSCS appeared in momentum scanners moving up ~5% while PAVM moved down ~3.7%. Other peers showed varied single‑stock moves, and BMRA’s own direction was not yet defined, indicating this MHRA news was stock-specific rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Therapy outcomes data	Positive	-5.1%	Reported real‑world inFoods IBS pain and bloating responder data plus reimbursement milestones.
Feb 18	International product approval	Positive	+0.0%	Vietnam approval for EZ Detect colorectal screening test and nationwide distribution agreement.
Jan 14	Earnings and outlook	Negative	-0.6%	Q2 FY2026 results with lower revenue, losses, and emphasis on cost controls and pivot.
Dec 23	Reimbursement milestone	Positive	+10.6%	CMS set a $300 national Medicare rate and CPT PLA code for inFoods IBS test.
Dec 11	Portfolio authorization	Positive	+3.2%	Egyptian Drug Authority authorized full rapid screening test portfolio for marketing.

Pattern Detected

BMRA has often moved in line with regulatory/market access wins, but some recent positive data and approval news saw flat or negative next-day reactions.

Recent Company History

Over the past few months BMRA has focused on expanding diagnostics access and managing financial strain. On Dec 11, 2025, Egypt authorized its full rapid screening portfolio, followed by a $300 CMS Medicare rate for inFoods IBS on Dec 23, 2025. Subsequent Q2 FY2026 results on Jan 14, 2026 highlighted lower sales and going‑concern risks. Vietnam then approved EZ Detect™ on Feb 18, 2026, and real‑world inFoods IBS data were released on Feb 26, 2026. Today’s MHRA registration for hp+detect™ extends this international commercialization theme into the UK.

Market Pulse Summary

This announcement adds another international milestone for BMRA, granting MHRA registration that ena...

Analysis

This announcement adds another international milestone for BMRA, granting MHRA registration that enables hp+detect™ sales to UK laboratories. The test targets H. pylori, which infects an estimated 35% of the U.S. population, 45% in Europe’s five largest countries, and 44% globally, and is linked to gastric cancer, the third leading cause of cancer-related death. In the context of recent financial filings citing weaker sales and going‑concern language, investors may watch how quickly UK partnerships convert into revenue and how this complements existing inFoods IBS and other screening products.

Key Terms

mhra, h. pylori, helicobacter pylori, carcinogen, +1 more

5 terms

mhra regulatory

"Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain"

The MHRA is the United Kingdom’s government agency that checks and approves medicines, medical devices and vaccines before they can be sold, and monitors their safety once on the market. For investors, MHRA decisions act like a building inspector’s sign-off or a traffic controller’s clearance—approval clears the way for sales and revenue, while safety warnings, recalls or delays can slow launches, raise costs or hurt a product’s commercial prospects.

h. pylori medical

"The Biomerica hp+detect™ product detects H. pylori bacteria, which is estimated to infect 35%..."

A common stomach bacterium that can live in the lining of the stomach and upper intestine, often causing chronic inflammation, sores (ulcers), and increasing the risk of stomach cancer. For investors, H. pylori matters because testing, treatments and vaccines create ongoing markets for diagnostics, pharmaceuticals and public-health programs, and shifts in infection rates, drug resistance or new therapies can change revenue and regulatory risk for companies in those areas.

helicobacter pylori medical

"hp+detect™ diagnostic test that detects Helicobacter pylori (H. pylori) bacteria."

Helicobacter pylori is a curved bacterium that lives in the stomach and can cause long‑lasting inflammation, peptic ulcers and higher risk of stomach cancer. For investors it matters because the bacterium’s widespread infection drives demand for tests, treatments, antibiotics and potential vaccines, affecting clinical trial activity, regulatory approvals and sales—like a persistent leak that creates ongoing repair costs and market opportunities.

carcinogen medical

"The WHO has designated H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant..."

A carcinogen is any substance, radiation, or mixture that can cause cells in the body to change and grow uncontrollably, leading to cancer. Investors care because discovery or exposure can trigger costly recalls, lawsuits, regulatory restrictions, cleanup expenses and lasting damage to a company’s sales and reputation—like a spark that can start a long, expensive fire that harms both people and business value.

antimicrobial resistance medical

"therapy in an era of increasing antimicrobial resistance."

Antimicrobial resistance is when microbes such as bacteria, viruses or fungi evolve so that medicines meant to kill them no longer work — like a lock changing so the old key no longer fits. For investors, this increases demand and cost for new treatments, prolongs hospital stays, prompts tougher regulation and can shrink sales of once-effective drugs, affecting pharmaceutical revenues, R&D spending and broader healthcare risk.

AI-generated analysis. Not financial advice.

Registration marks the Company’s entry into the UK market, where H. pylori affects an estimated 45% of the population across Europe’s five largest countries

• UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
• Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
• Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.
  

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced that it has received official registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ diagnostic test that detects Helicobacter pylori (H. pylori) bacteria. This product will now be marketed to labs throughout the UK for the detection of H. pylori infection in patients.

The Biomerica hp+detect™ product detects H. pylori bacteria, which is estimated to infect 35% of the U.S. population and 45% of the population in Europe’s five largest countries. H. pylori infection is the strongest known risk factor for gastric cancer, which is the third most common cause of cancer-related death worldwide. The WHO has designated H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health. Physicians and medical centers will be able to use hp+detect™ to diagnose H. pylori infection and monitor efficacy of treatments used to eradicate the infection.

H. pylori is one of the most prevalent bacterial infections worldwide, affecting an estimated 44% of the global population. It is the leading cause of peptic ulcer disease and a primary driver of gastric cancer — the third most common cause of cancer-related death globally. In the United Kingdom, H. pylori infection remains a significant public health burden, and the availability of accurate, non-invasive diagnostic tools is critical to enabling timely clinical intervention and appropriate antibiotic therapy in an era of increasing antimicrobial resistance.

“Receiving MHRA registration for hp+detect™ is a meaningful commercial milestone that expands our international reach into the United Kingdom,” said Zack Irani, CEO of Biomerica. “The UK represents an important addressable market given the high prevalence of H. pylori infection across Europe. This registration reflects our ongoing commitment to delivering innovative diagnostic solutions to patients and clinicians worldwide.”

About Biomerica (Nasdaq: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s estimated future financial results, demand for the Company’s products, the Company’s ability to fulfill orders, regulatory clearance of the Company’s tests and products, and the possible success of our products once introduced into the market. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the safety and efficacy of the Company’s hp+detect™ test and actual safety and efficacy in patients; acceptance, adoption and sales of the hp+detect™ product within the medical community in the UK; regulatory approvals necessary prior to commercialization in additional countries, including FDA clearance; availability of the Company’s test kits and other products; capacity, resource and constraints on our suppliers; competition from other similar products and from competitors that have significantly more financial and other resources available to them; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold; and the Company’s ability to obtain patent protection and freedom to operate on any aspects of its diagnostic technologies. Accordingly, such future financial results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Investor Contact: Zack Irani | +1 949-645-2111 | investors@biomerica.com
Source: Biomerica, Inc.

FAQ

What does Biomerica's MHRA registration for hp+detect™ mean for BMRA shareholders?

Direct answer: MHRA registration permits commercial sales of hp+detect™ in Great Britain, opening a new revenue market for BMRA. According to the company, the registration authorizes marketing to UK labs and supports active partner discussions to commercialize the test.

When did Biomerica (BMRA) receive MHRA registration for hp+detect™?

Direct answer: Biomerica announced MHRA registration on March 5, 2026, for hp+detect™ in Great Britain. According to the company, this formal registration authorizes commercial marketing to diagnostic laboratories across the UK.

How does hp+detect™ address H. pylori prevalence referenced by Biomerica (BMRA)?

Direct answer: hp+detect™ is intended to diagnose H. pylori infection and monitor treatment efficacy in patients. According to the company, H. pylori affects about 35% of the U.S. population and 45% in Europe’s five largest countries.

Will Biomerica (BMRA) immediately sell hp+detect™ in UK labs after MHRA registration?

Direct answer: The company can market hp+detect™ in Great Britain following MHRA registration but commercial rollout depends on partner agreements. According to the company, it is in active discussions with UK partners and will announce finalized deals.

Why is hp+detect™ registration significant amid antimicrobial resistance concerns for BMRA?

Direct answer: Registration provides clinicians a non-invasive diagnostic option to guide appropriate antibiotic therapy for H. pylori. According to the company, WHO lists H. pylori among antibiotic-resistant threats, underscoring diagnostic importance.